StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

Kalaris Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Kalaris Therapeutics's enterprise value was -$48.27M on Nov 11, 2026, against $116.63M a year earlier. Over the last 5 years it ranged from -$135.83M to $541.65M, with a median of $5.65M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$48.27M-130.6%
2025Dec 31, 2025$157.77M–
2024Dec 31, 2024-$73.42M–
2023Dec 29, 2023-$135.83M-164.3%
2022Dec 30, 2022$211.12M-61.0%
2021Dec 31, 2021$541.65M-72.8%
2020Dec 31, 2020$1.99B–

More Kalaris Therapeutics figures

See a number that looks wrong?